CIHR team grant in HIV vaccine discovery: novel mechanisms and strategies of protection University of Toronto KAVI University of Nairobi. Presenter: Dr Julius Oyugi. HIV Vaccine Team. University of Toronto Mario Ostrowski [PI] Tania Watts Jen Gommerman Goetz Erhardt Rupert Kaul
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
CIHR team grant in HIV vaccine discovery: novel mechanisms and strategies of protectionUniversity of TorontoKAVI University of Nairobi
Presenter: Dr Julius Oyugi
University of Toronto
University of Nairobi
Theme 1: Optimizing CD8 T cell memory for prophylactic or therapeutic immunization.
Theme #2: Optimizing and targeting mucosal
Aim 1: Pre-clinical development of a canarypox (ALVAC) expressing HIV antigens and TNF-SF (tumor necrosis factor superfamily) molecules.
Aim 2: Pre-clinical development of immunotherapeutic approaches targeting costimulatory and coinhibitory pathways to improve T cell function in HIV infection.
Aim 3: Determining the feasability of a persistent replicating virus vector for HIV vaccine development: the role of pre-existing vector immunity on mucosal T cell immunity and activation.
VZV based Vaccine as a vector
Goal is to determine whether a VZV based vaccine could;
Aim 5: To investigate the feasibility of blocking the HIV Env/ T cell integrinα4β7/b1 interaction as a strategy to reduce mucosal acquisition of HIV.
Team member Philpott is Nod expert
Test ability of candidate NLR agonists to enhance antibody responses at the mucosal level.
Progress: Have begun testing Nod 2 agonist (MDP) and a novel nod agonist (AHL) in a DNA vaccine and protein vaccine approach using gp120 in Balb/C mice.
Aim 7: Development and standardization of mucosal immune assays focused on B cell responses to be applied to vaccination studies in the Kenyan cohort.
Progress: Obtained Envclade A and C during early infection